{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041736","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.550316+00:00","generated_at":"2026-06-02T03:33:09.519151+00:00","sec_items":["3.01","3.03","5.03","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nasdaq staff determination to delist Heart Test Laboratories; company plans appeal and 1-for-100 reverse split","bullets":["Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).","Company intends to appeal by May 16, 2024; hearing will stay delisting pending Panel decision.","Board filed Certificate of Amendment for a 1-for-100 reverse stock split to regain compliance.","Reverse split also adjusts warrants; exercise price changes to $425.00 per share.","Shareholders approved split at Jan 2024 annual meeting; board selected 1-for-100 ratio on May 6, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041736","json":"https://secwatch.observer/filing/0001213900-24-041736.json","markdown":"https://secwatch.observer/filing/0001213900-24-041736.md","text":"https://secwatch.observer/filing/0001213900-24-041736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024041736/0001213900-24-041736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024041736/ea0205776-8k_heart.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:33:09.519151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1b99701fdc0ae76f4106eb8c8d5134c0ca4f1c7","claim":"HeartSciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).","evidence_excerpt":"May 9, 2024, the Company received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of May 8, 2024, the Company’s Common Stock had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company may appeal the Staff Determination to a Nasdaq Hearings Panel (the “Panel”) by filing a hearing request wit","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024041736/0001213900-24-041736-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5810(c)(3)(A)(iii)"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}